Literature DB >> 24197892

Vertebral aspergillosis in a patient with autosomal-dominant hyper-IgE syndrome.

Hong Ma1, Lei Kuang, Guohua Lv, Bing Wang, Zhesi Lian.   

Abstract

We present a report of an autosomal-dominant hyper-IgE syndrome patient with vertebral aspergillosis. Early diagnosis and antifungal therapy with surgery are crucial for improving the outcome of this aggressive condition.

Entities:  

Mesh：

Substances：

Year:  2013        PMID： 24197892      PMCID： PMC3910922          DOI： 10.1128/CVI.00529-13

Source DB:  PubMed          Journal:  Clin Vaccine Immunol        ISSN： 1556-679X


  10 in total

1.  Dominant-negative mutations in the DNA-binding domain of STAT3 cause hyper-IgE syndrome.

Authors:  Yoshiyuki Minegishi; Masako Saito; Shigeru Tsuchiya; Ikuya Tsuge; Hidetoshi Takada; Toshiro Hara; Nobuaki Kawamura; Tadashi Ariga; Srdjan Pasic; Oliver Stojkovic; Ayse Metin; Hajime Karasuyama
Journal:  Nature       Date:  2007-08-05       Impact factor: 49.962

2.  STAT3 mutations in the hyper-IgE syndrome.

Authors:  Steven M Holland; Frank R DeLeo; Houda Z Elloumi; Amy P Hsu; Gulbu Uzel; Nina Brodsky; Alexandra F Freeman; Andrew Demidowich; Joie Davis; Maria L Turner; Victoria L Anderson; Dirk N Darnell; Pamela A Welch; Douglas B Kuhns; David M Frucht; Harry L Malech; John I Gallin; Scott D Kobayashi; Adeline R Whitney; Jovanka M Voyich; James M Musser; Cristina Woellner; Alejandro A Schäffer; Jennifer M Puck; Bodo Grimbacher
Journal:  N Engl J Med       Date:  2007-09-19       Impact factor: 91.245

3.  Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America.

Authors:  Thomas J Walsh; Elias J Anaissie; David W Denning; Raoul Herbrecht; Dimitrios P Kontoyiannis; Kieren A Marr; Vicki A Morrison; Brahm H Segal; William J Steinbach; David A Stevens; Jo-Anne van Burik; John R Wingard; Thomas F Patterson
Journal:  Clin Infect Dis       Date:  2008-02-01       Impact factor: 9.079

Review 4.  Spinal aspergillus osteomyelitis.

Authors:  F C Vinas; P K King; F G Diaz
Journal:  Clin Infect Dis       Date:  1999-06       Impact factor: 9.079

5.  Invasive fungal disease in autosomal-dominant hyper-IgE syndrome.

Authors:  Donald C Vinh; Janyce A Sugui; Amy P Hsu; Alexandra F Freeman; Steven M Holland
Journal:  J Allergy Clin Immunol       Date:  2010-04-14       Impact factor: 10.793

6.  Voriconazole drug monitoring in the management of invasive fungal infection in immunocompromised children: a prospective study.

Authors:  Pere Soler-Palacín; Marie Antoinette Frick; Andrea Martín-Nalda; Miguel Lanaspa; Leonor Pou; Eva Roselló; Cristina Diaz de Heredia; Concepció Figueras
Journal:  J Antimicrob Chemother       Date:  2011-12-21       Impact factor: 5.790

Review 7.  Aspergillosis case-fatality rate: systematic review of the literature.

Authors:  S J Lin; J Schranz; S M Teutsch
Journal:  Clin Infect Dis       Date:  2001-01-26       Impact factor: 9.079

8.  [Height and weight standardized growth charts for Chinese children and adolescents aged 0 to 18 years].

Authors:  Hui Li; Cheng-Ye Ji; Xin-Nan Zong; Ya-Qin Zhang
Journal:  Zhonghua Er Ke Za Zhi       Date:  2009-07

Review 9.  Defects in Jak-STAT-mediated cytokine signals cause hyper-IgE syndrome: lessons from a primary immunodeficiency.

Authors:  Yoshiyuki Minegishi; Hajime Karasuyama
Journal:  Int Immunol       Date:  2008-12-15       Impact factor: 4.823

10.  Aspergillus vertebral osteomyelitis in chronic leukocyte leukemia patient diagnosed by a novel panfungal polymerase chain reaction method.

Authors:  Lior Dayan; Hannah Sprecher; Amos Hananni; Hana Rosenbaum; Victor Milloul; Ilana Oren
Journal:  Spine J       Date:  2007-02-12       Impact factor: 4.166
  10 in total
  1 in total

Review 1.  Clinical Manifestations and Genetic Analysis of 17 Patients with Autosomal Dominant Hyper-IgE Syndrome in Mainland China: New Reports and a Literature Review.

Authors:  Jing Wu; Ji Chen; Zhi-Qing Tian; Hao Zhang; Ruo-Lan Gong; Tong-Xin Chen; Li Hong
Journal:  J Clin Immunol       Date:  2017-02-14       Impact factor: 8.317
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.